Format

Send to

Choose Destination
Drug Des Devel Ther. 2012;6:261-72. doi: 10.2147/DDDT.S29928. Epub 2012 Sep 26.

Current and novel drug therapies for idiopathic pulmonary fibrosis.

Author information

1
Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.

Abstract

Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the aims of those treating IPF have shifted from reversing the disease to slowing or preventing progression of this chronic fibrotic illness. It is to be hoped that by slowing disease progression, survival will be improved from the current dismal median of 3.5 years following diagnosis. In Europe and Asia, a milestone has recently been reached with the licensing of the first IPF-specific drug, pirfenidone. This review assesses the current treatment modalities available for IPF, including pirfenidone. It also turns an eye to the future and discusses the growing number of promising compounds currently in development that it is hoped, in time, will make their way into the clinic as treatments for IPF.

KEYWORDS:

acute exacerbations; clinical trials; interstitial lung disease; pirfenidone; usual interstitial pneumonia

PMID:
23055696
PMCID:
PMC3463380
DOI:
10.2147/DDDT.S29928
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center